Document Detail

Postresection surveillance for pancreatic cancer performance status, imaging, and serum markers.
MedLine Citation:
PMID:  23187849     Owner:  NLM     Status:  In-Data-Review    
ABSTRACT: Approximately 15% of patients with a diagnosis of pancreatic adenocarcinoma are candidates for potentially curative surgery. However, most patients who undergo such surgery will die from recurrent disease, most within the first few years, whereas nearly all succumb by 5 to 7 years from diagnosis. Currently, there is a lack of high-level evidence to guide consensus recommendations as to the optimal surveillance strategy after resection. There is considerable variability in clinical practice, ranging from frequent clinical follow-up, with serial Ca 19-9 measurement and routine computed tomographic imaging on a 3- to 6-monthly basis, to a practice of no routine serum or imaging follow-up after surgery. In most part, this divergence in practice reflects a lack of data to define optimal practice. The argument in favor of limited surveillance presumably stems from the relatively uniform poor outcomes after recurrence and the absence of evidence indicating that early detection of local, regional, or metastatic recurrence improves outcomes. However, recent advancements in the treatment of metastatic disease offer hope that earlier detection and initiation of treatment for recurrent disease may positively impact clinical outcomes and at least urges review of the topic. One advantage to the development of defined guidelines would be greater consistency in the setting of both routine clinical follow-up and follow-up after adjuvant therapy on trial.
Eileen M O'Reilly; Maeve A Lowery
Related Documents :
23020209 - Independent predictors of survival and the impact of repeat surgery in patients undergo...
22054889 - A decade of advances in treatment of early-stage lung cancer.
23052739 - Clinical outcome of up-front surgery in patients with asymptomatic, incurable synchrono...
8980989 - Radiation pneumonitis complicating mediastinal radiotherapy postpneumonectomy.
21773909 - Stromal sarcoma of the breast with lung metastases showing a clinical complete response...
24587879 - Risk factors and survival outcomes for patients with anastomotic leakage after surgery ...
25132169 - Surgical management of well-differentiated thyroid carcinoma in children and adolescent...
21508399 - High-risk group for locoregional recurrence in patients with stage ib-iib squamous cell...
20390419 - A phase i/ii trial of the oral antiangiogenic agent tsu-68 in patients with advanced he...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Cancer journal (Sudbury, Mass.)     Volume:  18     ISSN:  1540-336X     ISO Abbreviation:  Cancer J     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-11-28     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100931981     Medline TA:  Cancer J     Country:  United States    
Other Details:
Languages:  eng     Pagination:  609-13     Citation Subset:  IM    
From the *Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY; and Weill Medical College of Cornell University, New York, NY; and †Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A neoadjuvant strategy for the management of nonmetastatic pancreatic cancer.
Next Document:  Postresection chemotherapy for pancreatic cancer.